Logo Medical Science Monitor Basic Research

Call: 1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo Medical Science Monitor Basic Research Logo Medical Science Monitor Basic Research Logo Medical Science Monitor Basic Research

01 November 1996

High doses of alphacalcidol given once a week - a new method of treatment of uraemic secondary hyperparathyroidism

Ewa Pacocha, Joanna Matuszkiewicz-Rowińska, Stanisław Niemczyk, Marek Świtalski, Barbara Bogdańska-Straszyńska, Kazimierz Ostrowski

Med Sci Monit 1996; 2(6): CR784-788 :: ID: 500494

Abstract

High dose pulse iv or oral 1,25 (OH)2,D3,/1(αOH)D3, therapy in uremic hyperparathyroidism has been shown to be much more effective than daily standard doses. The problem of hypercalcemia, however, still exists. Since in the last years protracted fall in serum PTH was found after a single dose of 1,25 (OH)2,D3, we decided to check whether 1(αOH)D3, administrated once weekly is effective in parathyroid hyperactivity of chronic renal failure. 17 hemodialysis patients with advanced hyperparathyroidism were given oral alphacalcidol in doses of 6 (g once a week, during the dialysis session. Dialysate calcium was 1.40 - 1.45 moll/l, and CaCO3, (up to 6 g/day) was used as the main phosphate binder; in 6 patients Al(OH)3, (up to 3 g/day) was added. The doses of 1 (αOH)D3,CaCO3, and Al(OH)3, were modified according to the calcium and phosphate levels. Serum 1 - 84 PTH decreased significantly after 2 weeks (p (0.02), and then the reduction of parathyroid activity progressed to 51&plusm;6.1&percnt; at the end of the study. The normalisation of PTH secretion was seen only in one patient and the treatment was ineffective in 4 patients; 3 of them had initial serum PTH levels (800 pg/ml. The serum 1,25 (OH)2,D3, levels increased from 8.5±1.08 pg/ml to 17.0±2.72 pg/ml (p<0.025). Serum total calcium, phosphate, alkaline phosphatase activity and hydroxyproline levels did not change significantly, nor did the doses of 1α(OH)D3,CaCO3, and Al(OH)3,. The incidence of hypercalcemia was 2.6% hese results indicate that oral pulse therapy with alphacalcidol administered once a week effectively reduces PTH secretion in hemodialysis patients with moderate hyperparathyroidism, with low risk of hypercalcemia and oversuppression of parathyroid activity.

Keywords: alphacalcidol, chronic renal failure, uremic hyperparathyroidism, hemodialysis

Comments

Most Viewed Current Articles

13 Apr 2020 : Original article  

Outcome of 24 Weeks of Combined Schroth and Pilates Exercises on Cobb Angle, Angle of Trunk Rotation, Chest...

DOI :10.12659/MSMBR.920449

Med Sci Monit Basic Res 2020; 26:e920449

11 May 2020 : Original article  

Analysis of Psychological and Sleep Status and Exercise Rehabilitation of Front-Line Clinical Staff in the ...

DOI :10.12659/MSMBR.924085

Med Sci Monit Basic Res 2020; 26:e924085

05 Jan 2021 : Review article  

A Southeast Asian Perspective on the COVID-19 Pandemic: Hemoglobin E (HbE)-Trait Confers Resistance Against...

DOI :10.12659/MSMBR.929207

Med Sci Monit Basic Res 2021; 27:e929207

10 Aug 2020 : Clinical Research  

Effects of Cognitive Task Training on Dynamic Balance and Gait of Patients with Stroke: A Preliminary Rando...

DOI :10.12659/MSMBR.925264

Med Sci Monit Basic Res 2020; 26:e925264

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor Basic Research eISSN: 2325-4416
Medical Science Monitor Basic Research eISSN: 2325-4416